The Scottish Sun reports fewer than 800 people in Scotland have been prescribed Wegovy or Mounjaro on the NHS, leaving thousands paying out of pocket.
Recap by typeshit. Full story at The Scottish Sun.
Hanmi set Eppe's first four weeks at 129,800 won ahead of a late-month launch, while Novo seeks Korean insurance coverage for Wegovy in high-risk patients.
Novo trades near 11.8 times forward earnings against an 18.6 average, and the piece asks whether that makes it a buying chance or a value trap.
About half of Australia's roughly 500,000 GLP-1 users pay privately, A$200 to $700 a month, and the authors argue cost hits those with the most obesity hardest.
Ireland's drug pricing body recommended semaglutide over tirzepatide for cost reasons, and Higgins says it's the right call, with a pun he didn't get to use.
BusinessWorld Online lists a new FDA warning covering weight loss drugs such as Wegovy. The listing doesn't say what the warning is about, so check the source for details.
On India Today, the two weighed the benefits of GLP-1 medicines against misuse, with concerns raised about cosmetic use for weight loss.
Loading…